HAVCR2 and glioblastoma: Other inhibitory and checkpoint receptors that have garnered less attraction for therapeutic targeting, such as TIM-3, may be more vital for overall tumor-driven immunosuppression in the glioblastoma setting, especially as TIM-3 (unlike many other checkpoint receptors) is over-expressed in glioblastoma tumor tissue and correlates with glioblastoma patients’ progression-free survival.